Differentiating Parkinson's Disease from Other Parkinsonian Disorders

ABSTRACT

In 1817, James Parkinson formally described the shaking palsy that is now known as idiopathic Parkinson's disease (PD). Symptoms of PD, however, existed for thousands of years before that time. Descriptions evolved significantly until the term parkinsonism was eventually coined to describe neurologic disorders characterized by the presence of tremor, rigidity, and bradykinesia in addition to loss of postural reflexes and freezing. In this article, we present some useful clinical pearls in distinguishing idiopathic PD from atypical parkinsonism or drug-induced parkinsonism.

KEYWORDS

Parkinsonism - parkinsonian plus - atypical parkinsonism - tardive movements - drug-induced parkinsonism

REFERENCES

• 1 National Institute of Neurological Disorders and Stroke .Parkinson's disease backgrounder. http://Available at: www.ninds.nih.gov/disorders/parkinsons_disease/parkinsons_disease_backgrounder.htm Accessed August 7, 2007
• 2 Dewey R. Clinical features of Parkinson's disease. In: Adler CH, Ahlskog JE Parkinson's Disease and Movement Disorders: Diagnosis and Treatment Guidelines for the Practicing Physicians. Totowa, NJ; Humana Press 2000: 297-319
• 3 Fahn S, Ford B. Medical treatment of Parkinson's disease and its complications. In: Noseworthy JH Neurological Therapeutics: Principles and Practice. London, New York; Taylor and Francis 2003: 2447-2482
• 4 Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner W J. Practice parameter. Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 2006;  66 968-975
• 5 Paulson H L, Stern M B. Clinical manifestations of Parkinson's disease. In: Watts RL, Koller WC Movement Disorders: Neurologic Principles and Practice. 2nd ed. New York, NY; McGraw-Hill 2004: 233-245
• 6 Hurtig H. What is Parkinson's disease? Neuropathology, neurochemistry, and pathophysiology?. In: Adler CH, Ahlskog JE Parkinson's Disease and Movement Disorders: Diagnosis and Treatment Guidelines for the Practicing Physicians. Totowa, NJ; Humana Press 2000: 57-70
• 7 MD Virtual University .Parkinson's disease. http://Available at: www.mdvu.org/library/disease/pd/par_path.html Accessed August 7, 2007
• 8 Ahlskog J E. Medication strategies for slowing the progression of Parkinson's disease. In: Adler CH, Ahlskog JE Parkinson's Disease and Movement Disorders: Diagnosis and Treatment Guidelines for the Practicing Physicians. Totowa, NJ; Humana Press 2000: 101-114
• 9 Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner W J. Practice parameter. Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 2006;  66 976-982
• 10 Miyasaki J M, Martin W, Suchowersky O, Weiner W J, Lang A E. Practice parameter. Initiation of treatment for Parkinson's disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 2002;  58 11-17
• 11 Worldwide Education and Awareness for Movement Disorders .Parkinson's disease. http://Available at: www.wemove.org/par/ Accessed August 7, 2007
• 12 Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease.  Neurology. 2003;  61 422-423
• 13 Klos K J, Bower J H, Josephs K A, Matsumoto J Y, Ahlskog J E. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.  Parkinsonism Relat Disord. 2005;  11 381-386
• 14 Hamani C, Neimat J, Lozano A M. Deep brain stimulation for the treatment of Parkinson's disease.  J Neural Transm Suppl. 2006;  70 393-399
• 15 Gelb D J, Oliver E, Gilman S. Diagnostic criteria for Parkinson's disease.  Arch Neurol. 1999;  56 33-39
• 16 Cordato N J, Halliday G M, Caine D, Morris J GL. Comparison of motor, cognitive, and behavior features in progressive supranuclear palsy and Parkinson's disease.  Mov Disord. 2006;  21 632-638
• 17 McMonagle P, Blair M, Kertesz A. Corticobasal degeneration and progressive aphasia.  Neurology. 2006;  67 1444-1451
• 18 Thomas M, Jankovic J. Parkinsonism plus disorders. In: Noseworthy JH Neurological Therapeutics: Principles and Practice. London, New York; Taylor and Francis 2003: 2483-2504
• 19 Litvan I, Booth V, Wenning G K. Retrospective application of a set of clinical criteria for the diagnosis of multiple system atrophy.  J Neural Transm. 1998;  105 217-227
• 20 Wenning G K, Colosimob C, Gesera F, Powe W. Multiple system atrophy.  Lancet Neurol. 2004;  3 93-103
• 21 We Move (Worldwide Education and Awareness for Movement Disorders). Pharmacological agents. http://Available at: www.wemove.org/myo/myo_phm Accessed August 7, 2007
• 22 Adler C H. Differential diagnosis of Parkinson's disease.  Med Clin North Am. 1999;  83 349-367
• 23 Hubble J P. Drug induced parkinsonism. In: Watts RL, Koller WC Movement Disorders: Neurologic Principles and Practice. 2nd ed. New York, NY; McGraw-Hill 2004: 395-402